Efficacy and Safety of Ainuovirine Treating With AIDS Patients

Last updated: June 13, 2022
Sponsor: Guangzhou 8th People's Hospital
Overall Status: Active - Recruiting

Phase

N/A

Condition

Hiv/aids

Hiv Infections

Aids And Aids Related Infections

Treatment

N/A

Clinical Study ID

NCT05420246
X220314682
  • Ages 18-60
  • All Genders

Study Summary

Ainuovirine is the third generation of non nucleoside reverse transcriptase inhibitors(NNRTIs), for the treatment of HIV-1 infected adults. The existing clinical studies show that Ainuovirine is safe and potent, it solves the problem from the first-generation NNRTIs such as Efavirenz with large side effects and the second-generation like Rilpivirine not suitable for high viral load, but there are no relevant data or reports on the efficacy and safety of Ainuovirine in HIV-infected patients in China so far. This project aims to explore the efficacy and safety of ART regimens containing Ainuovirine for HIV-infected patients in real clinical environment, in further to guide clinical application.

Eligibility Criteria

Inclusion

Inclusion Criteria: Diagnosis of HIV infection 18-60 years old Patients who are prescribed to take Ainuovirineregimen . Sign informed consent

Exclusion

Exclusion Criteria:

  1. Patients who are participating in other interventional clinical trials;
  2. Patients who previously participated in the ACC007 study.

Study Design

Total Participants: 450
Study Start date:
May 01, 2022
Estimated Completion Date:
December 31, 2025

Study Description

This study is an open-label, multicentered, single-arm and phase IV clinical trial.

450 HIV-infected patients who received Ainuovirine regimen (150mg, oral, qd) were included. At day 1 (1st collection as day 1), 3rd, 6th, 9th, 12th month, the rate of viral suppression and CD4+T cell count were calculated against baseline. In addition, the safety and drug compliance were also monitored.

Other indicators:

Demographic data (including gender, ethnicity, age, height, education level, occupation, route of infection), past medical history, smoking history, drug abuse history, hepatitis B markers, hepatitis C antibody, B ultrasound, chest X-ray, electrocardiogram, pregnancy test (Females of childbearing age): Day 1 (1st collection as Day 1), 1 time in total.

Vital signs (heart rate, blood pressure), body weight: 5 times on day 1 (the 1st collection was taken as day 1), 3rd, 6th, 9th, and 12th months.

Connect with a study center

  • Guangzhou 8th People's Hospital, Guangzhou Medical University.

    Guangzhou, Guangdong 510060
    China

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.